First City Capital Management Inc. Has $271,000 Position in Ionis Pharmaceuticals, Inc. (IONS)
First City Capital Management Inc. continued to hold its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,330 shares of the company’s stock at the end of the second quarter. First City Capital Management Inc.’s holdings in Ionis Pharmaceuticals were worth $271,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of IONS. Hanseatic Management Services Inc. raised its position in Ionis Pharmaceuticals by 1.2% during the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after purchasing an additional 41 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in Ionis Pharmaceuticals by 0.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 9,673 shares of the company’s stock worth $492,000 after buying an additional 43 shares during the period. Public Employees Retirement Association of Colorado lifted its holdings in Ionis Pharmaceuticals by 0.3% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock worth $1,241,000 after buying an additional 65 shares during the period. Utah Retirement Systems lifted its holdings in Ionis Pharmaceuticals by 0.5% in the 1st quarter. Utah Retirement Systems now owns 22,000 shares of the company’s stock worth $884,000 after buying an additional 100 shares during the period. Finally, World Asset Management Inc lifted its holdings in Ionis Pharmaceuticals by 3.4% in the 2nd quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock worth $286,000 after buying an additional 187 shares during the period. 89.24% of the stock is currently owned by institutional investors.
In other news, SVP C Frank Bennett sold 10,000 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $59.29, for a total transaction of $592,900.00. Following the completion of the sale, the senior vice president now owns 25,041 shares in the company, valued at approximately $1,484,680.89. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Patrick R. O’neil sold 1,000 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. Following the sale, the senior vice president now owns 10,633 shares of the company’s stock, valued at approximately $584,815. The disclosure for this sale can be found here. Insiders have sold 38,500 shares of company stock valued at $2,122,175 in the last three months. 1.86% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “First City Capital Management Inc. Has $271,000 Position in Ionis Pharmaceuticals, Inc. (IONS)” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/first-city-capital-management-inc-has-271000-position-in-ionis-pharmaceuticals-inc-ions/1603349.html.
Shares of Ionis Pharmaceuticals, Inc. (IONS) traded up 0.77% during trading on Monday, reaching $51.09. 257,246 shares of the company were exchanged. Ionis Pharmaceuticals, Inc. has a 1-year low of $24.58 and a 1-year high of $60.01. The firm has a market capitalization of $6.35 billion, a P/E ratio of 245.62 and a beta of 3.12. The firm’s 50 day moving average is $51.73 and its 200 day moving average is $48.15.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The firm had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The firm’s quarterly revenue was up 170.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.47) EPS. On average, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post ($0.17) EPS for the current fiscal year.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 target price on the stock in a research note on Monday, July 31st. TheStreet upgraded shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, July 5th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Sunday, September 17th. Barclays PLC assumed coverage on shares of Ionis Pharmaceuticals in a report on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price objective for the company. Finally, BMO Capital Markets restated an “outperform” rating and issued a $62.00 price objective (up from $59.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, July 12th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. Ionis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $49.11.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.